1-3 of 3
Shannon Marshall
Close
Sort by
Journal Articles

Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing

Evgeny Arons, PhD, Daniel Gorelik, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Mark Sokolsky, Hong Zhou, Nai Shun (nancy) Yao, MD, Shannon Marshall, PhD, Katherine Potocka, Erin Fykes, Ira Pastan, MD, Robert J. Kreitman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1861.
https://doi.org/10.1182/blood-2018-99-113419
Published: 2018
Journal Articles

Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study

Robert Kreitman, MD, Martin S. Tallman, MD, Tadeusz Robak, MD PhD, Steven Coutre, MD, Shannon Marshall, PhD, Jie Yang, PhD, Ira Pastan, MD, Nai Shun (Nancy) Yao, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2765.
https://doi.org/10.1182/blood.V130.Suppl_1.2765.2765
Published: 2017
Journal Articles

Sigma 2-Agonist CB-64D Induces Apoptosis in Non Hodgkin’s Lymphoma Cells: Association with Decreased Akt Expression.

Chiara Dell’Agnola, MD, Wojciech Wojciechowski, PhD, Shannon Marshall, Natalia E. Lopez, DDS, Huifen Li, PhD, Wayne D. Bowen, PhD, Igor J. Espinoza-Delgado, MD
Journal: Blood
Blood (2004) 104 (11): 4619.
https://doi.org/10.1182/blood.V104.11.4619.4619
Published: 2004